SCHEMBL3408091

SCHEMBL3408091

O=C(c1ccc(-c2ccc(Br)cc2)o1)N1CCOCC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.74
NPC1 O15118 7/20 0.74
PKM P14618 2/20 0.74
PDE4B Q07343 2/20 0.62
SMN1; SMN2 Q16637 5/20 0.57
MAPT P10636 4/20 0.57
HSD17B10 Q99714 2/20 0.57
USP2 O75604 1/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
ALDH1A1 P00352 5/20 0.56
KDM4E B2RXH2 2/20 0.56
LMNA P02545 3/20 0.55
HPGD P15428 2/20 0.55
PRNP P04156 1/20 0.55
SCN5A Q14524 1/20 0.54
SCN2A Q99250 1/20 0.54
SCN10A Q9Y5Y9 1/20 0.54
HTT P42858 1/20 0.54
MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030346 0.86 NPC1 (0.55) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL21717780 0.84 PDE4B (0.64) RAB9ANPC1PKMPDE4BSMN1; SMN2
SCHEMBL3150435 0.79 ALDH1A1 (0.59) RAB9ANPC1SMN1; SMN2TSHRALDH1A1
SCHEMBL19368119 0.77 CTSC (0.53) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL1772275 0.76 ERN1 (0.60) RAB9ANPC1PKMPDE4BSMN1; SMN2
SCHEMBL3403054 0.75 NPC1 (1.00) RAB9ANPC1SMN1; SMN2MAPTMAPK1
SCHEMBL967889 0.75 HPGD (0.70) PKMSMN1; SMN2MAPTTSHRMAPK1
SCHEMBL25062644 0.73 ALDH1A1 (0.60) RAB9ANPC1SMN1; SMN2TSHRALDH1A1
SCHEMBL9491011 0.73 ALDH1A1 (0.80) PKMSMN1; SMN2MAPTHSD17B10USP2
SCHEMBL25275688 0.73 ALDH1A1 (0.71) RAB9ANPC1PKMPDE4BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators NIH-DEITR 2017-07-06 US claimed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US claimed
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-04 US claimed
WO-2014145205-A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-09-18 WO claimed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 EP claimed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US claimed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO claimed
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2025-03-27 US disclosed
US-12239651-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2025-03-04 US disclosed
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-12-03 US disclosed
US-20240299432-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2024-09-12 US disclosed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 US disclosed
US-11963968-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-04-23 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299432-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 RAB9A 1434/4885NPC1 1607/4885PKM 4311/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 RAB9A 2455/4885NPC1 1630/4885PKM 4849/4885
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators WNT1, CTNNB1, CTNNBL1 RAB9A 4314/4885NPC1 1011/4885PKM 3791/4885
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells HES1, NOTCH1, NOTCH4 RAB9A 3020/4885NPC1 1656/4885PKM 4618/4885
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS HES1, NOTCH1, NOTCH4 RAB9A 3020/4885NPC1 1656/4885PKM 4618/4885
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS WNT1, CTNNB1, CTNNBL1 RAB9A 4168/4885NPC1 966/4885PKM 3766/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP RAB9A 3293/4885NPC1 1018/4885PKM 4678/4885
US-12239651-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 RAB9A 1434/4885NPC1 1607/4885PKM 4311/4885
US-11963968-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 RAB9A 1434/4885NPC1 1607/4885PKM 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.